Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Exclusion Criteria

• •Patient expected to require a surgical treatment of the fistula during the study
• •Patient having uncontrolled intra-abdominal sepsis; Crohn's disease; radiotherapy lesions of the small bowel; a mesenteric vascular insufficiency; a fistula localised in cancer-infiltrated areas; a distal obstruction; an exposed fistula of the small intestine; or intra-abdominal foreign bodies.
• •Patient receiving long-term corticotherapy
• •Patient having received any somatostatin analogue as curative treatment of the fistula or any PRF somatostatin analogue within the previous month.
• •Patient having previously undergone a transplant